Genmab — Februar 2023
-
Men OK - jeg ved godt, at det er “in”
-
morningstar - To really accelerate growth, we believe AbbVie needs to invest more in research and development (R&D). Spending at close to 13% of sales on R&D, AbbVie trails the industry average of high teens. Nevertheless, the firm holds a few key pipeline drugs, and we are most excited about cancer drug epcoritamab (approval likely in 2023). https://www.morningstar.com/articles/1136567/abbvie-posts-solid-q4-but-competitive-pressures-to-limit-long-term-growth
-
Tak for link, E L. Der var noget mere faktaorienteret i den artikel, at forholde sig til
-
INFO. Undersøgelser viser, at langt de fleste professionelle handlende bruger teknisk analyse til deres handel. Statistisk set bruger 80% af alle professionelle handlende teknisk analyse, mens de resterende 20% vælger andre teknikker såsom fundamental analyse. Så set ud fra det synspunt er det naturligt at TA fylder lidt i diverse invester forums.
-
Godmorgen.
-
Jeg er enig Stockbull. TA fylder meget lidt i chats og debat her på sitet i. Det uagtet at interessen er meget stor. Dine TA tråde i debatten og dem fra TheNote har rigtig mange læsere. Det samme med de langsigtede trendanalyser fra Rida vi havde fornøjelsen af i en periode. Han starter snart op igen på Proinvestor.
-
Rida´s TA analyser har vi liggende her. De bliver opdateret i den kommende tid:
https://www.proinvestor.com/analyser -
Jeg glemte selvfølgelig at nævne Nordicstock og Hans-Henrik Nielsen. Sidsnævnte har for øjeblikket travlt med sin TA-baseret fond. Derfor er der langt mellem hans videoer i debatten for øjeblikket.
-
Stoxx: Til gengæld lægger europæisk health care op til et teknisk brud opad
Kursgraf: Med stigende renter kan sektor-rotationen ud af tech over i defensiv healthcare blive accelereret.
Økonomisk Ugebrev (ugebrev.dk)
-
Dagens aktie er Genmab $GENMAB - international bioteknologisk virksomhed med speciale i antistofterapi til behandling af kræft.
4 stk. proprietære teknologier DuoBody, HexaBody, DuoHexaBody og HexElect
1.560 ansatte
Kommer med årsrapport d. 22 februar 2023.
Go big or go home https://twitter.com/dagensaktiedk/status/1623692890835677185 -
AbbVie (ABBV) Q4 2022 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2023/02/09/abbvie-abbv-q4-2022-earnings-call-transcript/#:~:text=We delivered full year 2022,of combined sales in 2022.
-
We also anticipate regulatory approvals this year for epcoritamab in relapsed refractory large B-cell lymphoma in several major geographies, including the U.S. in the second quarter and in Europe and Japan in the second half of the year.
Based on the very deep and durable responses demonstrated thus far in our clinical program, we believe that epcoritamab has the potential to significantly improve upon treatment options for these patients.
-
We believe that epcoritamab has the potential to become a core therapy for B-cell malignancies. And we continue to make very good progress expanding our development programs for epcoritamab across several indications. Over the course of 2023, we expect to begin several new studies, including a phase 3 study in front-line DLBCL in combination with R-CHOP and multiple phase 2 studies in CLL and MCL.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind